The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma

The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma

Summary: Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin's lymphoma and one of the most challenging blood cancers to combat due to frequent relapse after treatment. Here, we developed the first-in-class BTK/PI3K/BRD4 axis inhibitor SRX3262, which simultaneously blocks three i...

Full description

Bibliographic Details
Main Authors:	Dhananjaya Pal, Kendra R. Vann, Shweta Joshi, Namood E. Sahar, Guillermo A. Morales, Dalia El-Gamal, Tatiana G. Kutateladze, Donald L. Durden
Format:	Article
Language:	English
Published:	Elsevier 2021-09-01
Series:	iScience
Subjects:	Medical Biochemistry Molecular Physiology Cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589004221008993

Similar Items

Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells
by: Yamit Shorer Arbel, et al.
Published: (2021-05-01)

Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer
by: Zhu Z, et al.
Published: (2020-05-01)

Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice.
by: Steven D Schutt, et al.
Published: (2015-01-01)

Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia
by: Alexander P. de Porto, et al.
Published: (2019-01-01)

Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes
by: Sining Zhu, et al.
Published: (2021-08-01)

Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
by: Bartosz Puła, et al.
Published: (2019-11-01)

Mantle Cell Lymphoma: Effectiveness of Maintenance Ibrutinib – Case Report
by: Danuta Krasowska, et al.
Published: (2020-09-01)

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
by: Xiaohong Zhao, et al.
Published: (2017-04-01)

Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma
by: Aliénor Galinier, et al.
Published: (2017-01-01)

Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience
by: Young‐Woo Jeon, et al.
Published: (2019-11-01)

A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia
by: Tucker DL, et al.
Published: (2015-06-01)

Ibrutinib significantly inhibited Bruton’s tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model
by: Yaya Chu, et al.
Published: (2019-01-01)

Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
by: Lauren E. Kueffer, et al.
Published: (2021-06-01)

Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma
by: Zhuojun Liu, et al.
Published: (2021-06-01)

Draft genome sequence of Bradyrhizobium sp. strain BR 3262, an effective microsymbiont recommended for cowpea inoculation in Brazil
by: Jean Luiz Simões-Araújo, et al.

Selection and a 3-Year Field Trial of Sorangium cellulosum KYC 3262 Against Anthracnose in Hot Pepper
by: Sung-Chul Yun
Published: (2014-09-01)

Ibrutinib Treatment of Mantle Cell Lymphoma Relapsing at Central Nervous System: A Case Report and Literature Review
by: Donato Mannina, et al.
Published: (2017-01-01)

Molecular Epidemiological Screening of the Genome of the Strain Coxiella burnetii NL3262 (Netherlands, 2009) Using Formal Order Analysis
by: S. N. Shpynov, et al.
Published: (2019-01-01)

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
by: Raji E Joseph, et al.
Published: (2020-11-01)

Distal chromosome 1q aberrations and initial response to ibrutinib in central nervous system relapsed mantle cell lymphoma
by: Marcus Høy Hansen, et al.
Published: (2021-01-01)

Ibrutinib Treatment through Nasogastric Tube in a Comatose Patient with Central Nervous System Localization of Mantle Cell Lymphoma
by: Tamim Alsuliman, et al.
Published: (2018-01-01)

Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice
by: Vladimir I. Vorobyev, et al.
Published: (2021-07-01)

How to use ibrutinib
by: Е. А. Nikitin, et al.
Published: (2017-04-01)

Ibrutinib-induced cardiomyopathy
by: Htay Htay Kyi, et al.
Published: (2019-01-01)

Real‐world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis
by: Jun Ho Yi, et al.
Published: (2021-03-01)

Bruton’s Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells
by: Xing-Duo Dong, et al.
Published: (2020-08-01)

Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors
by: Erika Rimondi, et al.
Published: (2021-07-01)

Genomic identification and characterization of the elite strains Bradyrhizobium yuanmingense BR 3267 and Bradyrhizobium pachyrhizi BR 3262 recommended for cowpea inoculation in Brazil
by: Jakson Leite, et al.

Molecular investigations of BtK and WASP
by: MacCarthy-Morrogh, Lucy
Published: (1998)

Targeting Solid Tumors With BTK Inhibitors
by: Fatih M. Uckun, et al.
Published: (2021-04-01)

Life-threatening disseminated enterovirus infection during combined rituximab and ibrutinib maintenance treatment for mantle cell lymphoma: a case report
by: Maximilian Higer, et al.
Published: (2020-08-01)

Intermediate Results of Prospective Observational Study: The 2-year Experience of Ibrutinib Therapy in Relapsed/Refractory Mantle Cell Lymphoma in Clinical Practice
by: VI Vorob’ev, et al.
Published: (2019-03-01)

Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)
by: Michael Wang, et al.
Published: (2017-11-01)

Rapid progression after ibrutinib discontinuation in a patient with mantle cell lymphoma who has severe coronavirus disease 2019 infection
by: Fehmi Hindilerden, et al.
Published: (2021-03-01)

Toll-Like Receptor Signaling Drives Btk-Mediated Autoimmune Disease
by: Jasper Rip, et al.
Published: (2019-01-01)

Three years of ibrutinib in CLL
by: Forconi, Francesco
Published: (2015)

Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide
by: Alexandra Albertsson-Lindblad, et al.
Published: (2019-08-01)

Preparation data of the bromodomains BRD3(1), BRD3(2), BRD4(1), and BRPF1B and crystallization of BRD4(1)-inhibitor complexes
by: Martin Hügle, et al.
Published: (2016-06-01)

Current and novel BTK inhibitors in Waldenström’s macroglobulinemia
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2021-02-01)

Targeting the NLRP3 Inflammasome via BTK
by: Alexander N. R. Weber, et al.
Published: (2021-02-01)